Skip to main content

Table 1 General characteristics of the patients

From: Efficacy and safety of ivermectin in the treatment of mild to moderate COVID-19 infection: a randomized, double-blind, placebo-controlled trial

Variables Total (n = 72) Treatment (n = 36) Control (n = 36)
n (%) n (%) n (%)
Gender
 Male 27 (38) 14 (39) 13 (36)
 Female 45 (63) 22 (61) 23 (64)
Age (years), Mean ± SD 48.57 ± 14.80 49.42 ± 14.29 47.72 ± 15.45
 <40 years 18 (25) 10 (28) 8 (22)
 40–65 years 46 (64) 22 (61) 24 (67)
 >65 years 8 (11) 4 (11) 4 (11)
Underlying diseases
 Diabetes 17 (24) 11 (31) 6 (17)
 Hypertension 29 (40) 16 (44) 13 (36)
 Dyslipidemia 25 (35) 16 (44) 9 (25)
 Ischemic heart disease 2 (3) 1 (3) 1 (3)
 Peripheral arterial disease 0 (0) 0 (0) 0 (0)
 Malignancy 0 (0) 0 (0) 0 (0)
 HIV 0 (0) 0 (0) 0 (0)
 Cerebrovascular disease 2 (3) 0 (0) 2 (6)
 Alcoholism 0 (0) 0 (0) 0 (0)
 Chronic liver disease 0 (0) 0 (0) 0 (0)
 Chronic kidney disease stage 5 (7) 2 (6) 3 (8)
 Others 29 (40) 13 (36) 16 (44)
Known mode of transmission 26 (36) 15 (42) 11 (31)
COVID-19 vaccine 48 (67) 23 (64) 25 (69)
 1 dose 34 (47) 18 (50) 16 (44)
 2 dose 13 (18) 5 (14) 8 (22)
 Booster dose 1 (1) 0 (0) 1 (3)
 AstraZeneca 41 (57) 20 (56) 21 (58)
 Sinovac 3 (4) 2 (6) 1 (3)
 Sinopharm 5 (7) 1 (3) 4 (11)
Time from last vaccine (days), median (IQR) 57 (34–66) 59 (38–70) 44 (11–64)
  1. Abbreviations: IQR interquartile range